Cellectar Looks to Raise $3.3M
Cellectar Biosciences today announced it is looking to raise $3.3 million through Wednesday by pricing common stock at $2.20 per share. According to a release, the company looks to use the…
Tag Archives: Cellectar Biosciences
Cellectar CEO to Speak at Investment Conference
Cellectar Biosciences CEO Jim Caruso was chosen to present at the Rodman & Renshaw 17th Annual Global Investment Conference, taking place Sept. 10 in New York City, the organization announced recently. “The…
Jim Caruso to Head Cellectar
Cellectar Biosciences named Jim Caruso to be its new President and CEO, the company announced today. “(Jim) brings a level of energy and commitment, combined with his significant industry experience that…
Cellectar Begins Multiple Melanoma Trial
Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has initiated patient dosing in a proof-of-concept trial of I-131-CLR1404 in those with multiple melanoma. “I-131-CLR1404…
Cellectar Applies for Cancer Study
Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has applied to the U.S. Food & Drug Administration to begin a clinical study of a highly-selective,…
Cellectar Names New CEO
Cellectar Biosciences announced Wednesday that Acting CEO Simon Pedder, PhD., has been promoted to president and CEO. Dr. Pedder began his new role on Tuesday. “I am … appreciative of…
